Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Sarepta Therapeutics
(NQ:
SRPT
)
146.35
+0.74 (+0.51%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Sarepta Therapeutics
< Previous
1
2
...
6
7
8
9
10
11
12
13
Next >
3D Systems, CarGurus, Sarepta Therapeutics And Other Big Stocks Moving Higher On Wednesday
March 01, 2023
U.S. stocks traded lower, with the Dow Jones dropping around 80 points on Wednesday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Sarepta Rockets And Breaks Out As FDA Smooths The Path For Its Gene Therapy
March 01, 2023
The FDA will not hold an advisory committee meeting for the company's gene therapy.
Via
Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2023
March 01, 2023
Via
Benzinga
Novavax Stock Down On Concern Over Whether The Company Can Continue
February 28, 2023
Novavax warns that it may not be able to continue as a company.
Via
Talk Markets
Expert Ratings for Sarepta Therapeutics
February 15, 2023
Via
Benzinga
Why Is Sarepta Therapeutics (SRPT) Stock Up 21% Today?
March 01, 2023
Sarepta Therapeutics (SRPT) stock is heading higher on Wednesday following the release of its latest earnings report and an upgrade.
Via
InvestorPlace
Investors Just Hit the Jackpot on These 2 Nasdaq Biotech Stocks
March 01, 2023
Markets are trying to rise, and these companies are helping out.
Via
The Motley Fool
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
March 01, 2023
Via
Benzinga
Sarepta Therapeutics To Rally Over 53%? Here Are 10 Other Analyst Forecasts For Wednesday
March 01, 2023
Keybanc raised the price target for Ambarella, Inc. (NASDAQ: AMBA) from $95 to $105. Keybanc analyst John Vinh maintained an Overweight rating. Ambarella shares fell 7.1% to $87.61 in pre-market...
Via
Benzinga
Why Reata Pharmaceuticals Shares Are Trading Higher By 140%; Here Are 20 Stocks Moving Premarket
March 01, 2023
Gainers Reata Pharmaceuticals Inc (NASDAQ: RETA) rose 140.8% to $75.06 in pre-market trading after the company reported the FDA approval of SKYCLARYS for patients with Friedreich's Ataxia.
Via
Benzinga
9 Analysts Have This to Say About Sarepta Therapeutics
January 20, 2023
Via
Benzinga
BTIG Maintains Buy Rating for Sarepta Therapeutics: Here's What You Need To Know
December 22, 2022
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
March 01, 2023
It's time to start the day with another breakdown of the biggest pre-market stock movers traders need to know about on Wednesday!
Via
InvestorPlace
Sarepta Therapeutics (SRPT) Q4 2022 Earnings Call Transcript
February 28, 2023
SRPT earnings call for the period ending December 31, 2022.
Via
The Motley Fool
12 Health Care Stocks Moving In Tuesday's After-Market Session
February 28, 2023
Via
Benzinga
3 Gene Editing Stocks With the Best Long-Term Potential
January 25, 2023
These gene editing stocks are likely to deliver massive gains ahead in the fast-evolving biotech space
Via
InvestorPlace
Analyst Ratings for Sarepta Therapeutics
November 03, 2022
Within the last quarter, Sarepta Therapeutics (NASDAQ:SRPT) has observed the following analyst ratings:
Via
Benzinga
Sarepta Therapeutics (SRPT) Q3 2022 Earnings Call Transcript
November 03, 2022
SRPT earnings call for the period ending September 30, 2022.
Via
The Motley Fool
7 Analysts Have This to Say About Sarepta Therapeutics
October 13, 2022
Analysts have provided the following ratings for Sarepta Therapeutics (NASDAQ:SRPT) within the last quarter:
Via
Benzinga
Earnings Scheduled For February 28, 2023
February 28, 2023
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report earnings for its fourth quarter.
Via
Benzinga
7 Biotech Stocks That Will Make You Rich in 10 Years
January 18, 2023
Although the health innovation space is risky, the opportunities beckon a look at the biotech stocks that will make you rich in 10 years.
Via
InvestorPlace
2 Under-the-Radar Biotech Stocks to Buy in 2023
January 06, 2023
These biotechnology stocks are pushing ahead with promising innovations.
Via
The Motley Fool
2 Top Healthcare Stocks to Buy for the Long Haul
December 09, 2022
These two companies are just getting started.
Via
The Motley Fool
Stock Market Rally Fights At Key Level On Powell, Inflation Data, Jobs Report: Weekly Review
December 02, 2022
The S&P 500 is fighting for its 200-day, a critical level for the uptrend.
Via
Investor's Business Daily
Sarepta Surges As It Nears The Finish Line With A Muscular Dystrophy Gene Therapy
November 28, 2022
Sarepta Therapeutic is nearing the finish line with its Duchenne muscular dystrophy gene therapy.
Via
Investor's Business Daily
3 Unstoppable Stocks That Could Double in 5 Years
October 29, 2022
The opportunities for these innovators are tremendous.
Via
The Motley Fool
2 Under-the-Radar Biotech Stocks to Buy in 2022
October 19, 2022
These two drugmakers are growing in prominence.
Via
The Motley Fool
Apple To $177? Plus This Analyst Slashes PT On Opendoor Technologies By About 71%
October 17, 2022
Morgan Stanley cut Apple Inc. (NASDAQ: AAPL) price target from $180 to $177. Apple shares rose 1.1% to $139.95 in pre-market trading.
Via
Benzinga
PepGen's Duchenne Candidate Has Potential For Greater Exon Skipping Capabilities At Lower Doses Versus Sarepta's Candidate, Says Analyst
September 28, 2022
Via
Benzinga
Earnings Scheduled For November 2, 2022
November 02, 2022
Companies Reporting Before The Bell • Nomura Holdings (NYSE:NMR) is likely to report earnings for its second quarter.
Via
Benzinga
< Previous
1
2
...
6
7
8
9
10
11
12
13
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.